Updated on 2021/11/17

写真a

 
SUGARU Eiji
 
Organization
Research Institute of Environmental Medicine Designated associate professor
Title
Designated associate professor

Degree 1

  1. 博士(農学) ( 2006.9   京都大学 ) 

Research Interests 1

  1. 創薬科学

Research Areas 2

  1. Life Science / Metabolism and endocrinology

  2. Life Science / Tumor biology

 

Papers 22

  1. Weight loss and lipolysis promote a dynamic immune response in murine adipose tissue. Reviewed

    Aliki Kosteli, Sugaru E, Guenter Hammerle, Jayne Martin, Jason Lei, Rudolf Zechner, Anthony W Ferrante Jr.

    J Clin Invest.   Vol. 120 ( 10 ) page: 3466 - 3479   2010.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  2. C-C chemokine receptor 2 (CCR2) regulates the hepatic recruitment of myeloid cells that promote obesity-induced hepatic steatosis. Reviewed

    Obstfeld AE*, Sugaru E*, Thearle M, Francisco AM, Gayet C, Ginsberg HN, Ables EV, Ferrante AW Jr

    Diabetes.   Vol. 59 ( 4 ) page: 916 - 925   2010.4

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

  3. Amelioration of established diabetic nephropathy by combined treatment with SMP-534 (anti-fibrotic agent) and losartan in db/db mice. Reviewed

    Sugaru E, Nakagawa T, Ono-Kishino M, Nagamine J, Tokunaga T, Kitoh M, Hume WE, Nagata R, Taiji M.

    Nephron Experimental Nephrology   Vol. 105 ( 2 ) page: e45 - e52   2007

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

  4. SMP-534 ameliorates progression of glomerular fibrosis and urinary albumin in diabetic db/db mice. Reviewed

    Sugaru E, Nakagawa T, Ono-Kishino M, Nagamine J, Tokunaga T, Kitoh M, Hume WE, Nagata R, Taiji M.

    American Journal of Physiology Renal Physiology   Vol. 290 ( 4 ) page: F813 - F820   2006

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

  5. Enhanced effect of combined treatment with SMP-534 (anti-fibrotic agent) and losartan in diabetic nephropathy. Reviewed

    Sugaru E, Nakagawa T, Ono-Kishino M, Nagamine J, Tokunaga T, Kitoh M, Hume WE, Nagata R, Taiji M.

    American Journal of Nephrology   Vol. 26 ( 1 ) page: 50 - 58   2006

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

  6. SMP-534 inhibits TGF-beta-induced ECM production in fibroblast cells and reduces mesangial matrix accumulation in experimental glomerulonephritis. Reviewed

    Sugaru E, Sakai M, Horigome K, Tokunaga T, Kitoh M, Hume WE, Nagata R, Nakagawa T, Taiji M.

    American Journal of Physiology Renal Physiology   Vol. 289 ( 5 ) page: F998 - F1004   2005

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

  7. DSP-0692, a selective SCD inhibitor, enhances the anti-tumor activity of anti-PD1 antibody

    Eiji Sugaru, Yudai Furuta, Yoshikazu Nagagaki, Satoshi Ikeda, Yuichi Fukunaga, Hiroki Umehara, Tsuguteru Otsubo, Manabu Watanabe, Shingo Tojo, Miki Hashizume, Yasushi Matsuki, and Hitoshi Ban

    Cancer Res.   Vol. 79 ( 13 Supplement ) page: 3595 - 3595   2019.7

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (international conference proceedings)  

  8. Antibody intracellular activated drug conjugate (AiADC) as novel ADC technology

    Atsushi Suwa, Kazuo Komiya, Kenta Kadotsuji, Shoko Ochiai, Yosuke Takanashi, Eiji Sugaru, and Hitoshi Ban

    Cancer Res.   Vol. 79 ( 13 Supplement ) page: 223 - 223   2019.7

     More details

    Language:English   Publishing type:Research paper (international conference proceedings)  

  9. Intravenous administration of the selective toll-like receptor 7 agonist DSR-29133 leads to anti-tumor efficacy in murine solid tumor models which can be potentiated by combination with fractionated radiotherapy. Reviewed

    Dovedi SJ, Adlard AL, Ota Y, Murata M, Sugaru E, Koga-Yamakawa E, Eguchi K, Hirose Y, Yamamoto S, Umehara H, Honeychurch J, Cheadle EJ, Hughes G, Jewsbury PJ, Wilkinson RW, Stratford IJ, Illidge TM.

    Oncotarget.   Vol. 7 ( 13 ) page: 17035 - 17046   2016.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  10. TLR7 tolerance is independent of the type I IFN pathway and leads to loss of anti-tumor efficacy in mice. Reviewed

    Koga-Yamakawa E, Murata M, Dovedi SJ, Wilkinson RW, Ota Y, Umehara H, Sugaru E, Hirose Y, Harada H, Jewsbury PJ, Yamamoto S, Robinson DT, Li CJ.

    Cancer Immunol Immunother.   Vol. 64 ( 10 ) page: 1229 - 1239   2015.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  11. Discovery of 3H-imidazo[4,5-c]quinolin-4(5H)-ones as potent and selective dipeptidyl peptidase IV (DPP-4) inhibitors: use of a carboxylate prodrug to improve bioavailability. Reviewed

    Ikuma Y, Hochigai H, Kimura H, Nunami N, Kobayashi T, Uchiyama K, Umezome T, Sakurai Y, Sawada N, Tadano J, Sugaru E, Ono M, Hirose Y, Nakahira H.

    Bioorg Med Chem.   Vol. 23 ( 4 ) page: 779 - 790   2015.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  12. 2-({6-[(3R)-3-amino-3-methylpiperidine-1-yl]-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydro-5H-pyrrolo[3,2-d]pyrimidine-5-yl}methyl)-4-fluorobenzonitrile (DSR-12727): A potent, orally active dipeptidyl peptidase IV inhibitor without mechanism-based inactivation of CYP3A. Reviewed

    Nishio Y, Kimura H, Sawada N, Sugaru E, Horiguchi M, Ono M, Furuta Y, Sakai M, Masui Y, Otani M, Hashizuka T, Honda Y, Deguchi J, Nakagawa T, Nakahira H.

    Med Chem.   Vol. 19 ( 18 ) page: 5490 - 5499   2011.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  13. Discovery of new chemotype dipeptidyl peptidase IV inhibitors having (R)-3-amino-3-methyl piperidine as a pharmacophore. Reviewed

    Nishio Y, Kimura H, Tosaki S, Sugaru E, Sakai M, Horiguchi M, Masui Y, Ono M, Nakagawa T, Nakahira H.

    Bioorg Med Chem.   Vol. 20 ( 24 ) page: 7246 - 7249   2010.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  14. Chronic administration of DSP-7238, a novel, potent, specific and substrate-selective DPP IV inhibitor, improves glycaemic control and beta-cell damage in diabetic mice. Reviewed

    Furuta Y, Horiguchi M, Sugaru E, Ono-Kishino M, Otani M, Sakai M, Masui Y, Tsuchida A, Sato Y, Takubo K, Hochigai H, Kimura H, Nakahira H, Nakagawa T, Taiji M.

    Diabetes Obes Metab.   Vol. 12 ( 5 ) page: 421 - 430   2010.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  15. Combination therapy with SMP-534 and an angiotensin-converting enzyme inhibitor provides additional renoprotection in 5/6 nephrectomized rats. Reviewed

    Tsujimura T, Nagamine J, Sugaru E, Ono-Kishino M, Tokunaga T, Kitoh M, Nagata R, Nakagawa T, Taiji M.

    Biol Pharm Bull.   Vol. 32 ( 12 ) page: 1991 - 1996   2009.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  16. The anti-fibrotic agent SMP-534 attenuates bleomycin-induced pulmonary fibrosis in hamsters. Reviewed

    Tsujimura T, Ono-Kishino M, Nagamine J, Sugaru E, Tokunaga T, Kitoh M, Nagata R, Nakagawa T, Taiji M.

    Biomed Res.   Vol. 30 ( 3 ) page: 177 - 182   2009

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

  17. Chronic administration of SMP-534 ameliorates renal dysfunction in 5/6 nephrectomized rats. Reviewed

    Tsujimura T, Nagamine J, Sugaru E, Nakagawa T, Ono-Kishino M, Tokunaga T, Kitoh M, Nagata R, Taiji M.

    Nephron Exp Nephrol.   Vol. 110 ( 4 ) page: e99 - e108   2008

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  18. Brain-derived neurotrophic factor enhances glucose utilization in peripheral tissues of diabetic mice. Reviewed

    Yamanaka M, Tsuchida A, Nakagawa T, Nonomura T, Ono-Kishino M, Sugaru E, Noguchi H, Taiji M

    Diabetes, Obesity and Metabolism   Vol. 9 ( 1 ) page: 59 - 64   2007

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  19. Brain-derived neurotrophic factor ameliorates lipid metabolism in diabetic mice. Reviewed

    Tsuchida A, Nonomura T, Nakagawa T, Itakura Y, Ono-Kishino M, Yamanaka M, Sugaru E, Taiji M, Noguchi H.

    Diabetes, Obesity and Metabolism   Vol. 4 ( 4 ) page: 262 - 269   2002

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  20. Brain-derived neurotrophic factor (BDNF) regulates glucose and energy metabolism in diabetic mice. Reviewed

    Nakagawa T, Ono-Kishino M, Sugaru E, Yamanaka M, Taiji M, Noguchi H.

    Diabetes Metabolism Research Review   Vol. 18 ( 3 ) page: 185 - 191   2002

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  21. Brain-derived neurotrophic factor improved insulin sensitivity in obese fatty (fa/fa) Zucker rats. Reviewed

    Nakagawa T, Sugaru E, Taiji M.

    Biomedical Research   Vol. 23 ( 1 ) page: 11 - 15   2002

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  22. Unidirectional transport from apical to basolateral compartment of cobalt ion in polarized Madin-Darby canine kidney cells. Reviewed

    Nagao M, Sugaru E, Kambe T, Sasaki R.

    Biochemical and Biophysical Research Communications   Vol. 257 ( 2 ) page: 289 - 294   1999

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

▼display all